中文 EN ລາວ
Browse Products
Pharmaceutical Innovation
Global Innovative Pharmaceutical Company

Scientific Innovation
Safeguarding Life & Health

Deep expertise across 10 therapeutic areas, dedicated to innovative drug R&D for oncology, metabolism, hematology, infectious diseases and other major diseases, bringing hope and health to patients worldwide.

Explore Products R&D Pipeline
10
Therapeutic Areas
35
Marketed Products
12+
Pipeline Programs
Therapeutic Areas

10 Therapeutic Areas

Covering oncology, metabolism, hematology, infectious diseases and other major disease areas, delivering high-quality innovative treatments to patients worldwide

Oncology
Oncology
Oncology
5 Products · 3 Pipelines
Metabolism
Metabolism
Metabolism
3 Products · 2 Pipelines
Hematology
Hematology
Hematology
4 Products · 2 Pipelines
HIV & Infectious
HIV & Infectious
HIV & Infectious
4 Products · 0 Pipelines
Antibiotics
Antibiotics
Antibiotics
5 Products · 2 Pipelines
Anti-Inflammatory
Anti-Inflammatory
Anti-Inflammatory
3 Products · 1 Pipelines
HPV Vaccine
HPV Vaccine
HPV Vaccine
2 Products · 1 Pipelines
Growth Hormone
Growth Hormone
Growth Hormone
2 Products · 1 Pipelines
Burn Care
Burn Care
Burn Care
4 Products · 0 Pipelines
Hormone Deficiency
Hormone Deficiency
Hormone Deficiency
3 Products · 0 Pipelines
拖动或滚动浏览
Core Products

Core Products

Innovative medicines focused on major disease areas, bringing high-quality treatment options to patients globally

Osimertinib Oncology

Osimertinib

Osimertinib · 3rd-generation EGFR TKI

For adult patients with locally advanced or metastatic NSCLC with EGFR T790M mutation-positive

Learn More
Tirzepatide Metabolism

Tirzepatide

Tirzepatide · GIP/GLP-1 dual receptor agonist

For chronic weight management in obese or overweight adults and glycemic control in type 2 diabetes

Learn More
Imatinib Hematology

Imatinib

Imatinib · BCR-ABL tyrosine kinase inhibitor

Philadelphia chromosome-positive CML, ALL and gastrointestinal stromal tumors

Learn More
Bictegravir/FTC/TAF HIV & Infectious

Bictegravir/FTC/TAF

Bictegravir/FTC/TAF · Single-tablet triple regimen

Complete regimen for HIV-1 infection in adults and adolescents (≥25kg)

Learn More
View All Products
R&D Pipeline

R&D Innovation

We continue to invest in innovation, building cutting-edge platforms across monoclonal antibodies, ADCs, bispecifics, mRNA and gene therapy to address unmet medical needs.

12+
Pipeline Programs
4
Technology Platforms
2
Phase III Trials
View Pipeline
Discovery
0 projects
Phase I
4 projects
Phase II
5 projects
Phase III
2 projects
Registration/Approved
1 projects
News & Updates

News & Updates

Stay informed of Poseidon's latest R&D progress, product approvals and corporate updates

R&D Progress
August 15, 2026

NVP-201 Phase III Trial Achieves Positive Results with 87% PFS Improvement

Our 4th-generation EGFR inhibitor NVP-201 met its primary endpoint in the pivotal Phase III trial...

Read More →
Approvals
July 28, 2026

Novel Antibiotic NVP-412 Approved by NMPA

NMPA approved our novel cephalosporin antibiotic NVP-412 for complicated intra-abdominal infections...

Read More →
Partnerships
June 20, 2026

Gene Therapy R&D Partnership with National Academy of Medical Sciences

We signed a strategic cooperation agreement with the Institute of Hematology, CAMS, to jointly develop gene therapies...

Read More →
News & Updates

Creating a Healthier Future Together

Explore our innovative products and pipeline, and see how Poseidon brings hope to patients worldwide

Browse Products About Us